CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat. Phone: +91-79-68138700 Fax: +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

May 13, 2025

То

The Manager, Listing Department

General Manager, Listing Department

Department

Department

Department

National Stock Exchange of India Ltd. BSE Limited

Plot No. C/1 G Block, Phiroze Jeejabhoy Towers,

Bandra-Kurla Complex, Bandra (East),
Mumbai -400 051

Dalal Street,
Mumbai - 400 001

Symbol: CONCORDBIO Scrip Code: 543960

<u>Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Resignation of Company Secretary & Compliance Officer</u>

Dear Sir/Madam,

In compliance with provisions of Regulation 30 of SEBI (LODR) Regulations, 2015 read with Part-A of Schedule III of the said Regulations, we would like to inform that Mr. Prakash Sajnani has tendered his resignation today, 13th May, 2024 (Resignation letter attached below) from the position of Company Secretary & Compliance Officer of Concord Biotech Limited and request to be relieved from these responsibilities after the closing of working hours on 29th May 2025.

At present, Mr. Prakash Sajnani is designated as Assistant Vice President- Accounts & Finance as well as Company Secretary and Compliance Officer. The resignation has been submitted in view of the increased responsibilities in Accounts and finance department following the company's listing. The management has accepted the resignation effective from the close of business hours of May 29, 2025 and has approved the continuation of Mr. Prakash Sajnani in the role of "Assistant Vice President- Accounts & Finance"

The details required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 is provided in Annexure A.

Further, the Company has received confirmation from Mr. Prakash Sajnani that there are no other material reasons for his resignation other than those which are provided in the resignation letter which is annexed as Annexure B.

The Exchange is requested to take the same on record.

For Concord Biotech Limited

Ankur Vaid JMD and CEO DIN: 01857225

Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225. (India) Phone : +91-2714-222604, 398200 Fax : +91-2714-222504 Website : www.concordbiotech.com

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat. Phone: +91-79-68138700 Fax: +91-79-68138725 CIN No.: L24230GJ1984PLC007440 Email ID: complianceofficer@concordbiotech.com

Disclosure as required under Regulation 30 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024.

Reason for change viz resignation	At present, Mr. Prakash Sajnani is designated as Assistant Vice President-Accounts & Finance as well as Company Secretary and Compliance Officer. The resignation has been submitted in view of the increased responsibilities in Accounts and finance department following the company's listing. The management has accepted to relieve him from these responsibilities after the closing of working hours on 29th May, 2025. Accordingly, Mr. Prakash Sajnani will to continue serving the organization in the role of Assistant Vice President – Accounts
	& Finance
Date of Cessation	From the close of business hours on May 29, 2025
Brief Profile (in case of appointment);	Not Applicable
Disclosure of relationships between directors(in case of appointment);	Not Applicable

Mr. Prakash Sajnani will also cease to be Key Managerial Personnel under the provisions of Section 203 and other applicable provisions, if any, of the Companies Act, 2013 from the effective date of resignation.

Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225. (India) Phone : +91-2714-222604, 398200 Fax : +91-2714-222504 Website : www.concordbiotech.com

Date: 13th May' 2025

Joint Managing Director & CEO, Concord Biotech Limited, Ahmedabad, Gujarat.

Subject: Resignation from the Position of Company Secretary and Compliance Officer

Dear Sir,

I, Prakash Sajnani, have been designated as Assistant Vice President- Accounts & Finance as well as Company Secretary and Compliance Officer of M/s. Concord Biotech Limited. Since the Company's public listing, the responsibilities within the Accounts and Finance department have expanded significantly. This increase arises from the more rigorous regulatory framework and compliance standards applicable to listed entities, which now require timely and accurate quarterly financial closures, enhanced disclosure and reporting practices, and more complex taxation-related obligations.

Given the strategic importance of these functions in ensuring financial integrity and regulatory compliance, I am of the view that it would be most beneficial for the Company if I concentrate my efforts exclusively on these critical areas. This focused approach will enable me to contribute more effectively to the Company's financial governance and operational excellence in the evolving post-listing environment.

Therefore, I request you to consider this letter as my resignation from the position of Company Secretary and Compliance Officer of the Company, and request to be relieved from these responsibilities after the closing of working hours on 29th May 2025.

Accordingly, I will to continue serving the organization in the role of Assistant Vice President -Accounts & Finance, where I can dedicate my full attention and expertise to supporting the Company's evolving financial and regulatory needs.

I remain committed to ensuring a smooth transition and will extend my full cooperation in handing over the responsibilities to the designated successor.

I sincerely thank the Management for the trust and opportunities extended to me during my tenure in the current role.

Warm regards,

Brakach Lelahana

Assistant Vice President (Accounts & Finance)

Received & Acknowledged by Mo. Ankwa Void, JMD RCEO